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Abstract
HIV co-infection is an important risk factor for tuberculosis (TB) providing a powerful model
in which to dissect out defective, protective and dysfunctionalMycobacterium tuberculosis
(MTB)-specific immune responses. To identify the changes induced by HIV co-infection we
compared MTB-specific CD4+ responses in subjects with active TB and latent TB infection
(LTBI), with and without HIV co-infection. CD4+ T-cell subsets producing interferon-gamma
(IFN-γ), interleukin-2 (IL-2) and tumour necrosis factor-alpha (TNF-α) and expressing
CD279 (PD-1) were measured using polychromatic flow-cytometry. HIV-TB co-infection
was consistently and independently associated with a reduced frequency of CD4+ IFN-γ
and IL-2-dual secreting T-cells and the proportion correlated inversely with HIV viral load
(VL). The impact of HIV co-infection on this key MTB-specific T-cell subset identifies them
as a potential correlate of mycobacterial immune containment. The percentage of MTB-spe-
cific IFN-γ-secreting T-cell subsets that expressed PD-1 was increased in active TB with
HIV co-infection and correlated with VL. This identifies a novel correlate of dysregulated
immunity to MTB, which may in part explain the paucity of inflammatory response in the
face of mycobacterial dissemination that characterizes active TB with HIV co-infection.
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Introduction
HIV co-infection is the greatest risk factor for progression of latent tuberculosis infection (LTBI)
to active tuberculosis (TB) [1] and is associated with increased risk of de novo infection and re-
infection [2]. Data from SIV or HIV-TB co-infection indicate an increase in the risk of disease
reactivation prior to the onset of severe immunosuppression [3, 4]. This risk is not eliminated
with HIV therapy remaining at least twice that of the general population [5]. HIV co-infection
impacts the clinical phenotype of TB resulting in reduced cavitation, more severe disease,
increased bacillary dissemination and poorer outcomes in terms of morbidity and mortality.
This early, specific and lasting effect on MTB-specific immunity makes HIV and LTBI co-
infection a good model in which to dissect out defective, protective and dysfunctional MTB-
specific immune responses. LTBI may be viewed as the successful containment of infection by
effective anti-MTB immunity. Conversely, at the opposite end of the spectrum, active TB in the
setting of HIV co-infection represents a manifest failure of MTB resistance control character-
ised by bacillary dissemination, high bacterial load and higher mortality. Cellular immune
responses that specifically characterise this state, including cellular senescence [6] or immune
exhaustion phenotypes, may provide insight into cellular mechanisms of failed MTB-specific
immunity. MTB-specific cell subsets that are preferentially impaired or depleted by HIV infec-
tion are therefore candidates for correlation of immune containment and protective immunity.
Programmed death-1 (PD-1/CD279) is expressed by monocytes, CD4, CD8, NKT and B
cells and binds to its ligands PDL-1 and 2 inhibiting proliferation and cytokine production [7].
Expression on total CD4+ and CD8+ T-cells correlates with viral load (VL) and on HIV-spe-
cific CD8+ T-cells mediates immune dysfunction. Blockade of the PD-1 axis on HIV-specific
CD4+ and CD8+ cells can reverse this phenotype [7–11]. The PD-1 knock out mouse demon-
strated a highly inflammatory response to MTB infection [12]. In humans with active TB, PD-
1 expression correlated with IFN-γ production and prevention of ligand binding enhanced cel-
lular immune function [13]. The effect of HIV and MTB co-infection in active and LTBI on the
PD-1 axis in MTB-specific T-cells has not hitherto been investigated.
We hypothesized that in the setting of MTB infection, HIV co-infection would be associated
with a reduced frequency of particular CD4+ MTB-specific T-cell cytokine secreting subsets
and that this might serve as a correlate of MTB infection containment. Secondly, we hypothe-
sised that HIV-TB co-infection would be associated with increased expression of PD-1 indicat-
ing a possible cellular correlate for the deficit in MTB-specific immunity. We studied four key
clinical patient subgroups to delineate the impact of HIV in both stages of MTB infection. We
used multi-parameter flow cytometry to measure three canonical cytokines and PD-1 expres-
sion in patients with active TB, TB and HIV co-infection, LTBI and HIV co-infection and
LTBI as well as markers of T-cell exhaustion. This enabled simultaneous definition of func-
tional and phenotypic MTB-specific T-cell profiles at the single-cell level.
Materials and Methods
Participant selection
Enrolment was from three London centres, UK during 2008–2011. The samples and clinical
data used in this study were obtained from the TB Immunology Group Research Tissue Bank,
which was approved by the St Mary’s Research Ethics Committee (07/H0712/85). The Com-
mittee is constituted in accordance with the Governance Arrangements for Research Ethics
Committees (July 2001) and complies fully with the Standard Operating Procedures for
Research Ethics Committees in the UK. All samples were donated to the tissue bank after the
subjects had given written, informed consent and the research was approved by the Tissue
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Bank Steering Committee in accordance with the approved procedures for Tissue Banks in the
UK. Eligibility criteria included current investigation for active TB or LTBI or the presence of
risk factors for LTBI. All individuals underwent immune testing for MTB infection using a
Mycobacterium tuberculosis-specific blood test (IFN-γMTB ELISpot, as described below).
Active TB cases were all microbiologically confirmed. LTBI cases excluded those with symp-
tomatic, microbiological or radiological evidence of active TB. HIV infection was confirmed
according to national standards and HIV VL and CD4 T-lymphocyte counts were assayed in
the local Clinical Pathology Association accredited diagnostic laboratories at the time of study
recruitment. Participants were selected for flow cytometry analysis if they met strict case defini-
tion criteria for LTBI, active TB and/or HIV co-infection.
Definition of LTBI
A positive IFN-y response to ESAT-6 and CFP-10 and/or positive response to novel validated
MTB-specific peptides including MTB-specific peptides from Rv3873 [14, 15] and Rv3615c
[16]. Individuals with HIV co-infection were enrolled if they had risk factors for LTBI and
screened for the presence of LTBI [17]. All individuals with LTBI had a positive interferon
gamma release assay (IGRA) for MTB infection and/or tuberculin skin test.
Antigens
PPD was obtained from Serum Statens Institute and re-suspended in RPMI at 16.7μg/ml final
concentration. Pools of MTB-specific 15-mer overlapping peptides covering each of ESAT-6,
CFP-10, and Rv3615c were re-suspended in a single mixture (10μg/ml per peptide final
concentration).
IFN-γMTB ELISpot
Fresh or frozen peripheral blood mononuclear cells (PBMCs), 2.5 x 105 per well, were left
unstimulated or stimulated overnight (37°C 5% CO2 for 16 to 20 hours) with PHA, purified
protein derivative (PPD) and pools of MTB-specific 15-mer overlapping peptides covering
each of ESAT-6, CFP-10, EspC, TB7.7, Rv3879c, Rv3873 and Rv3878 in an IFN-γ capture ELI-
Spot assay as previously described [18]. Spot forming cells were counted using an AID ELISpot
reader. A positive response was at least 5 spot-forming cells more than the negative control
well and at least twice the negative control well. This method of diagnosing MTB infection in
the context of clinical data has been widely validated [19–22].
Intracellular cytokine staining
The cells were prepared as previously described [23], thawed PBMCs (3–5 x 106 per well) were
cultured for 16 hours (37°C 5% CO2) in 10% human serum in Roswell Park Memorial Institute
(RPMI) medium. Cells were stimulated with PMA-Ionomycin, (5ng/ml PMA and 500ng/ml
ionomycin final concentration), PPD or MTB-specific peptides or left unstimulated. After 2
hours Monensin (2 μM final concentration) was added. Cells were stained with a dead cell dis-
criminator (LIVE/DEAD1 Fixable Dead Cell Stain Kits, aqua, Invitrogen) (30 minutes, 4°C)
washed and placed in FC block buffer (10% human serum in filtered FACS solution: 0.5% bovine
serum albumin and 2mM EDTA in PBS) (20 minutes at 4°C). Cells were stained with titrated
fluorochrome-conjugated antibodies against CD3-APC-Alexa Fluor1750, CD4-Qdot1605 and
CD45RA-Qdot1655 (Invitrogen), CD8-APC, CCR7-PE-Cy™7 and CD127-FITC (BD Biosci-
ences) and PD-1-PerCP/Cy5.5 (Biolegend) then fixed and permeabilised with BD Cytofix/Cyto-
perm™ Fixation/Permeabilization kit (BD Biosciences) (20 minutes, 4°C). Cells were washed
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twice with Perm/Wash solution (BD Biosciences) were stained with optimised fluorochrome-
conjugated antibodies, IFN-γ-V450, IL-2-PE and TNF-α-AlexaFluor 700 (BD Biosciences) (30
minutes 4°C). Where possible, 1x106 events were acquired using a BD LSR-II flow cytometer and
compensation parameters set with Anti-Rat and Anti-Mouse Ig compensation beads (BD Biosci-
ences). Fluorescence minus one (FMO) controls were included each time. Data on CD8, CCR7,
CD45RA and CD127 are not included in this report, having been published separately but are
included in the methods for accuracy [23, 24].
Data analysis
FlowJo©TreeStar, Inc. v9.2 was used to gate on live cells, singlets and lymphocytes and CD3
+CD4+ subsets. FMO controls were used to define positive gates for IFN-γ, IL-2 and TNF-α
responses and PD-1 expression. Non-overlapping subsets of cytokine response were created
using Boolean analysis. Frequencies were normalised to the unstimulated control. Responders
had a response2 times the background and>0.001% of CD3+CD4+ T-cells and were ana-
lysed for PD-1 expression. Those without a positive response were excluded from phenotypic
analysis. Co-stimulatory molecules were not included in the assay to avoid signals not necessar-
ily present in vivo. Using these stringent cut-off criteria, antigen-specific rare events were
assumed to be real events.
Statistical analysis
This was conducted using IBM SPSS Statistics version 20 and Prism version 5. The Mann-
Whitney U test was used for two sample comparisons and Kruskal-Wallis test with Dunn’s
post-test comparison for multiple comparisons. Spearman’s Rank coefficient for tests of corre-
lation of non-parametric data was used. CD4 count and HIV VL were analysed as continuous
variables. A VL of 10 was designated where viral suppression was achieved.
Results
Participant characteristics
All individuals had a positive response to ESAT-6 or CFP-10 in the MTB-specific IFN-γ ELI-
Spot or T.SpotTB except one who had a TST>15mm and a positive response to Rv3615c. Rou-
tine HIV-screening is currently not undertaken in the UK for LTBI. All five patients where an
HIV test had not been clinically indicated had normal CD4/CD8 ratios. The median (IQR)
CD4 count (cells/μl) of those with TB/HIV and LTBI/HIV was 180 (136–200) and 455 (356–
530) and the median (IQR) VL (RNA copies/ml) was 28,958 (66–281,671) and 10 (10–12,691)
(Table 1). All individuals with TB or LTBI had received<14 days treatment for MTB except
one. 8 individuals with HIV infection were taking HAART at the time of blood sampling; two
(28.6%) TB/HIV subjects and six (60.0%) LTBI/HIV subjects, of whom 7 had suppressed viral
loads and one had a viral load of 66.
MTB-specific CD4+ T-cells secreting IFN-γ and IL-2 correlated inversely
with HIV viral load
We used Boolean gating to create 7 non-overlapping T-cell subsets secreting single or combi-
nations of 3 cytokines (IFN-γ, IL-2 and TNF-α) (S1 Fig). The frequency of these subsets was
compared to examine the impact of both HIV infection and active TB infection compared with
LTBI on MTB-specific T-cell responses. CD4+ MTB-specific T-cells secreting both IFN-γ and
IL-2 were reduced in frequency in individuals with HIV-TB co-infection (whether active or
latent) unlike other IL-2 secreting subsets (Fig 1). There was no difference in absolute
MTB-Specific CD4+ T-Cell Frequency and Phenotype in HIV-TB Co-Infection
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frequency of any CD4+ subset responding to PPD or MTB-peptides in those on HAART com-
pared with those not on HAART, however there was a trend towards a lower proportion of
IFN-γ and IL-2 dual secreting cells in those not taking HAART (S2 Fig). There was no differ-
ence in the frequency of MTB-specific CD4+ T-cells secreting IFN-γ and IL-2 in response to
PPD or MTB-peptides in individuals with active TB/HIV compared with LTBI/HIV or in
those with active TB compared with LTBI without HIV co-infection (data not shown). How-
ever the proportion of the total response to PPD or MTB peptides contributed by CD4+ T-cells
secreting IFN-γ and IL-2 together was lowest in active TB/HIV compared with LTBI without
HIV co-infection (S3 Fig).
There was an inverse relationship between the proportion of MTB-specific CD4+ IFN-γ
and IL-2-dual-secreting cells contributing to the total CD4+ T-cell cytokine response and HIV
VL (Rho = -0.694, p = 0.003) (Fig 2). Neither HIV VL nor CD4 count correlated with the pro-
portion of MTB-specific CD4+ IL-2-only-secreting T-cells. There was a weak association of
CD4 count with the proportion of MTB-specific tri-functional cells (Rho = 0.525, p = 0.037).
The proportion of MTB-specific CD4+ T-cell functional effectors secreting IFN-γ, TNF-α or
both was inversely correlated with CD4 count (IFN-γ only Rho = -0.518, p = 0.040 and dual
Rho = -0.633 p = 0.009) and correlated with HIV VL (TNF-α only Rho = 0.664, p = 0.005).
PD-1 expression on PPD-specific T-cells was related to HIV and active
TB co-infection and correlated with HIV viral load
We next investigated the expression of PD-1 (in those with a positive response) on MTB- spe-
cific T-cells (S4 Fig). Active TB with HIV co-infection was associated with a higher percentage
of MTB-specific CD4+ T-cells secreting IFN-γ alone expressing PD-1 compared to all other
Table 1. Participant characteristics.
TB/HIV TB LTBI/HIV LTBI Total
7 (%/IQR) 6 (%/IQR) 10 (%/IQR) 11 (%/IQR) 34 (%/IQR)
Age 43 (40,54) 35 (26,57) 37 (24,40) 34 (30,36) 36 (31,41)
Male 4 (57.1) 3 (50.0) 6 (60.0) 4 (36.4) 17 (50.0)
Female 3 (42.9) 3 (50.0) 4 (40.0) 7 (63.6) 17 (50.0)
Black African 5 (71.4) 1 (16.7) 8 (80.0) 6 (54.5) 20 (58.8)
Asian 1 (14.3) 4 (66.7) 0 (0.0) 3 (27.3) 8 (23.5)
Caucasian 1 (14.3) 1 (16.7) 2 (20.0) 2 (18.2) 6 (17.6)
HIV positive 7 (100.0) 0 (0.0) 10 (100.0) 0 (0.0) 17 (50.0)
HIV negative or untesteda 0 (0.0) 6 (100.0) 0 (0.0) 11 (100.0) 17 (50.0)
CD4 cells/μl 180 (136;200) NA NA 455 (356;530) NA NA NA NA
HIV viral load 28,958 (66;281,671) NA NA 10 (10;12,691) NA NA NA NA
HIV treated 2 (28.6) NA NA 6 (60.0) NA NA NA NA
HIV untreated 5 (71.4) NA NA 4 (40.0) NA NA NA NA
BCG vaccinated 5 (71.4) 3 (50.0) 9 (90.0) 8 (72.7) 25 (73.5)
BCG un vaccinated 1 (14.3) 2 (33.3) 0 (0.0) 2 (18.2) 5 (14.7)
not known 1 (14.3) 1 (16.7) 1 (10.0) 1 (9.1) 4 (11.8)
IGRA or tuberculin skin test positive 7 (100.0) 6 (100.0) 10 (100.0) 11 (100.0) 34 (100.0)
MTB infection conﬁrmed 7 (100.0) 6 (100.0) NA NA NA NA NA NA
a 5 individuals with LTBI did not undergo testing for HIV infection but had normal CD4/8 ratios
IGRA interferon gamma release assay
IQR interquartile range
doi:10.1371/journal.pone.0146905.t001
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Fig 1. HIV co-infection negatively impacts MTB-specific CD4+ functional cell subsets secreting IFN-γ and IL-2.Graphs show frequency and median
of CD4+ cell functional subsets secreting IFN-γ and IL-2 (top row) and IL-2 only (middle row) and IFN-γ, IL-2 and TNF-α (bottom row) in response to overnight
stimulation with PPD (left column) and MTB-peptides (right column). p values on graphs showMann-Whitney U tests for HIV-infected vs. HIV-uninfected
(n = 34). Closed circles represent those with TB, and open circles those with LTBI with or without HIV co-infection.
doi:10.1371/journal.pone.0146905.g001
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groups, p = 0.019 (Fig 3). Similarly the greatest frequency of PD-1 expression in MTB-specific
cells secreting IFN-γ and TNF-α was seen in patients with active TB /HIV co-infection
(p = 0.010) with a similar trend in tri-functional cells (Fig 3). The highest rates of PD-1 expres-
sion were therefore seen in patients with active TB / HIV co-infection.
HIV VL correlated with the percentage of MTB-specific CD4+ IFN-γ-only-secreting cells
that expressed PD-1, independently of the frequency of CD4+ IFN-γ-only secreting cells
(Rho = 0.811, p<0.001) (Fig 4). The percentage of MTB-specific CD4+ IFN-γ and TNF-α-dual
(Rho = 0.723, p = 0.002) and CD4+ tri-functional- (Rho = 0.653, p = 0.006) cells responding to
PPD (Fig 4) and CD4+IFN-γ and TNF-α-dual-secreting cells responding to MTB peptides
(Rho = 0.628 p<0.001) (data not shown) expressing PD-1 correlated with HIV VL. There was
an inverse correlation of the percentage of cells expressing PD-1 with CD4 count for PPD-
responsive CD4+ IFN-γ and TNF-α-dual-secreting cells (Rho = -0.618 p = 0.014), MTB-pep-
tides-responsive IFN-γ and TNF-α-dual (Rho = -0.802 p = 0.001) and IFN-γ-only-secreting
cells (Rho = -0.757 p = 0.021). These relationships were not observed in cell subsets not secret-
ing IFN-γ and overall the greatest PD-1 expression was seen in those with active TB / HIV co-
infection. A lower proportion of CD4+ MTB-specific cells, secreting IFN-γ alone, IFN-γ plus
TNF-α and all three cytokines in response to PPD, expressed PD-1, in those on HAART com-
pared with those not on HAART (p = 0.010, p = 0.031 and p = 0.031 respectively).
Discussion
CD4+ MTB-specific cells secreting IFN-γ and IL-2 may serve as a
correlate of containment in HIV-TB co-infection
Our data indicate potential HIV-induced correlates underlying the loss of containment of
MTB and the immune dysfunction in active TB contributing to the early and lasting effects of
Fig 2. HIV VL is negatively correlated with the proportion of CD4+ MTB-specific T-cells secreting IFN-
γ and IL-2.Graph shows Spearman’s rank correlation of proportion of PPD-specific CD4+ IFN-γ and IL-
2-dual-secreting cells with HIV VL. Participants with both active TB/HIV (closed circles) and LTBI/HIV (open
circles) and a positive response to PPD are shown (n = 16).
doi:10.1371/journal.pone.0146905.g002
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HIV co-infection and increased TB-related morbidity and mortality [4, 25, 26]. We previously
showed that HIV infection was associated with a reduced frequency of MTB-specific IFN-γ
and IL-2 dual-secreting CD4+ cells in patients with LTBI, most of whom had normal or near
normal CD4 counts due to immune restoration with HAART [24]. Here we see a greater
impact on this subset in patients that have not yet started HAART and furthermore an inverse
correlation with HIV VL. We found very little evidence of relationships between other MTB-
specific CD4+ T-cell subsets and HIV infection pinpointing IFN-γ and IL-2-dual secreting
cells as uniquely impacted by HIV infection. This may reflect an increasing inability to contain
MTB in individuals with uncontrolled HIV replication, although we were unable to prove cau-
sality in this cross sectional study. Our findings are consistent with the cumulative evidence for
an association of antigen-specific CD4+ cells secreting IL-2 with or without IFN-γ in the con-
tainment or resolution of viral and TB infections [24, 27–33]. The association of HIV VL with
reduced frequency of IL-2 secreting cells has been investigated but without an HIV-uninfected
control group for comparison [32, 34]. The relationship with increasing VL is consistent with
an effect mediated by on-going viral replication, such as specific killing but teasing out the
Fig 3. PD-1 expression by MTB-specific T-cells secreting IFN-γ is increased in active TB /HIV co-infection.Graphs show percentage, median and IQR
of PD-1 expression on CD4+ subsets secreting IFN-γ-only (top left), IFN- γ and TNF-α (top right) and IFN-γ, IL-2 and TNF-α (bottom left) following overnight
stimulation with PPD. Individuals without a positive response were excluded. p values show Kruskal-Wallis test with Dunn’s post-test comparison.
doi:10.1371/journal.pone.0146905.g003
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mechanisms of this HIV-induced antigen-specific cell death is complex. MTB-specific cells
may be lost early in HIV infection and IL-2-secreting cells may be more vulnerable to infection
with HIV [35, 36].
MTB-specific CD4+ functional effector responses and PD-1 expression
may reflect mycobacterial burden
The associations of MTB-specific CD4+ cells secreting IFN-γ with or without TNF-α (CD4
+ effector-like cells) with CD4 count and VL that we demonstrated likely reflects increasing
mycobacterial burden in patients with HIV and TB as previously shown [23, 37]. Active TB
with advanced HIV co-infection was characterised by a high frequency of the MTB-specific
IFN-γ-only-secreting subset and the expression of PD-1 may be linked to IFN-γ secretion [13].
Increased expression of PD-1 on CD4+ MTB-specific IFN-γ-secreting T-cells was associated
with HIV co-infection and correlated with VL. Given the role of PD-1 in immune regulation
Fig 4. Association of PD-1 expression on CD4+ MTB-specific T-cells secreting IFN-γwith HIV VL.Graphs show Spearman’s rank correlation of HIV VL
with the percentage of cells expressing PD-1, for PPD-specific CD4+ cells secreting IFN-γ-only (top left), IFN- γ and TNF-α (top right) and IFN-γ, TNF-α and
IL-2 (bottom left). Those without a positive response in the relevant functional subset were excluded. Those with TB/HIV (closed circles) and LTBI/HIV (open
circles) are shown.
doi:10.1371/journal.pone.0146905.g004
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and exhaustion and its close correlation with total CD4+ T-cell activation and immunosup-
pression in HIV infection [8, 11, 38–40], these data suggest a novel correlate of dysregulated
immunity that is a feature of active TB/HIV. Whilst these changes were also noted in those
with LTBI and HIV co-infection the greatest effect was in those with active TB and HIV co-
infection. Although our analysis of PD-1 expression on MTB-specific T-cells showed a corre-
late with HIV VL this was most marked in the patients where mycobacteria were likely to be
disseminated. HIV VL may therefore be acting as a surrogate marker of mycobacterial burden
driving PD-1 expression through T-cell receptor stimulation.
Studies in mice and humans indicate that in TB, PD-1 might function as a self-regulatory
and tissue-protective off-switch [12, 13, 41–44]. Our findings on MTB-specific T-cells in
HIV-TB co-infection might therefore underlie two observations that relate to the immune
‘exhaustion’ and tissue-protective functions of PD-1. The increased expression of PD-1 on
IFN-γ-secreting CD4+ T-cells might contribute to reduced ability to control MTB infection
and underpin the paucity of immunopathology as manifested by, for example, the lack of cavi-
tatory disease resulting in the increased bacillary load and dissemination that characterize
active TB/HIV.
Role of tri-functional cells
The frequency of MTB-specific CD4+ tri-functional T-cells secreting IFN-γ, IL-2 and TNF-α
was independent of both mycobacterial burden and HIV co-infection. Tri-functionality has
been associated with active TB [45, 46] but data from the mouse lung suggests an alternative
protective role [47] and polyfunctionality is a putative marker of protective immunity in vac-
cine trials [48]. We did not find sufficient evidence to suggest the tri-functional CD4+ T-cell
subset correlates with protection although there was a weak association in those who were
highly immunosuppressed. Some data have suggested that polyfunctional, less differentiated
cells might be increased at the site of extra-pulmonary TB in those with HIV co-infection [49].
Our data indicated that in PBMCs, neither the presence of polyfunctionality nor the frequency
of tri-functional cells was significantly affected by HIV co-infection or TB disease stage, which
detracts from its putative role as a peripheral marker of protection [50] or active TB [46], how-
ever in our limited sample size the presence of weak associations cannot be excluded.
Effect of HAART on MTB-specific CD4+ cell responses
The natural history of HIV and TB co-infection means that extricating the effects of HAART
from the effects of mycobacterial burden is challenging and beyond the scope of this study. We
were unable to control for the presence of HAART and although HIV VL may be taken as a
surrogate marker for its effects, the immunological outcomes we observed cannot be disentan-
gled from associated changes in mycobacterial burden.
Limitations of this work
Comprehensive analysis of a small number of precisely defined subjects has enabled us to
study MTB-specific T-cell responses in detail and to uncover the most significant relationships.
Other possible immunological effects cannot be ruled-out on account of our small sample size.
We are unable to infer causality based solely on the associations identified in this cross-sec-
tional study. Nevertheless, taken together these findings may have significance for monitoring
disease activity in MTB-infected individuals.
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Conclusions
Our detailed dissection of the effects of HIV-TB co-infection on the MTB-specific CD4+ T-cell
immune response has provided insight into clinically important features and indicated poten-
tially useful immune correlates for monitoring disease activity. Our data accords with mount-
ing evidence that MTB-specific T-cells secreting IL-2 with or without IFN-γ have a protective
role to play in immune containment and suggests that the dual-secreting cells may be of great-
est significance in this capacity. Secondly we identified a correlate of exhausted and dysregu-
lated antimycobacterial immunity in active TB with advanced HIV co-infection that may
partially explain certain characteristic clinical features of this life-threatening condition. Our
hypothesis is that the immunophenotype (cytokine secretion profile and expression of PD-1)
of the MTB-specific CD4+ T-cell response reflects the manifest failure of MTB containment in
HIV co-infection i.e. active TB. Clinical observations suggest that in the presence of HIV infec-
tion this failure is profound with widespread dissemination of MTB. This is indicated by both
the loss of CD4+ IFN-γ and IL-2 secreting cells and the increased frequency of PD-1 expres-
sion, which we observed in TB and HIV co-infection. If large longitudinal studies can prospec-
tively validate our findings, these correlates may help to pave the way for the development and
evaluation of new interventions to augment immune containment in LTBI and reverse
immune dysregulation in active TB.
Supporting Information
S1 Fig. Boolean gating of MTB-specific CD4+ functional cell subsets. PBMCs from donors
were left unstimulated or stimulated with PPD or MTB-specific peptides for 16 hours with
Monensin added after 2 hours. The cells were stained with a dead cell discriminator then fluo-
rescence-conjugated antibodies against phenotypic markers before fixing, permeabilising and
staining with antibodies targeting intracellular IFN-γ, IL-2 and TNF-α. Plots are representative
of one individual with active TB/HIV and show PBMCs stimulated with PPD. Single, live, CD3
+ lymphocytes were gated for CD4+ and CD8+ cells (top row). Gating was performed in two
dimensions for quadrants containing IFN-γ, IL-2 and TNF-α positive and negative cells, (mid-
dle row). Three-dimensional Boolean gating was used to select cytokine subsets; an example of
CD3+CD4+ IFN-γ-only-secreting cells is shown (bottom row) selecting only IFN-γ-only-
secreting cells from quadrants in the middle row (Q1, Q5 and Q12). Multi-dimensional Bool-
ean gating allows the user to exclusively select subsets secreting specific cytokines, which is rep-
resented 2-dimensionally here. For example selecting IFN-γ-only-secreting cells excludes all
cells secreting IL-2 or TNF-α.
(EPS)
S2 Fig. Frequency and proportion of CD4+ MTB-specific IFN-γ and IL-2 dual secreting
cells by HIV treatment status. Graphs show frequency of CD4+ MTB-specific T-cells secret-
ing IFN-γ and IL-2 (top) and proportion of CD4+ MTB-specific T-cells secreting IFN-γ and
IL-2 (bottom) in those with HIV infection on therapy or not on therapy. Those with TB/HIV
(closed circles) and LTBI/HIV (open circles) are shown.
(EPS)
S3 Fig. Proportion of MTB-specific CD4+ T-cells secreting IFN-γ and IL-2 of the total
response where there was a positive response.Upper panel shows response to PPD and lower
panel to MTB-peptides. Graphs show results of Kruskal-Wallis test with Dunn’s post-test com-
parison.
(EPS)
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S4 Fig. Gating strategy for PD-1 expression by MTB-specific CD4+ T-cells. Plots are repre-
sentative of one individual with active TB and HIV and show PBMCs stimulated with PPD.
Live, CD3+ lymphocytes were gated for CD4+ and CD8+ cells, then for quadrants containing
IFN-γ, IL-2 and TNF-α positive and negative cells, Boolean gating was used to select cytokine
subsets in 3 dimensions to generate 7 cytokine subsets, an example of CD3+CD4+ IFN-γ-only
secreting cells is shown and PD-1 expression was determined using PerCP-Cy5.5 fluorescence
minus one as a gating control.
(EPS)
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